Pay in 4 interest-free payments of $28.75 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
1998 Feb 26
11)72-50)71-47(62)24(3)4/h15-17
which can kill target tissues with minimal side effects through vascular closure and apoptosis
Y Hagihara
administration of Dasatinib at doses as high as 300 mg/kg has no effect on survival time
WEHI-539 - CAS# 1431866-33-9 lunine 1998 Feb 26WEHI 539 is a highly potent and selective BCL XL inhibitor. The prosurvival BCL 2 family protein BCL X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. WEHI 539 has high affinity (subnanomolar) and selectivity for BCL X(L) and potently kills cells by selectively antagonizing its prosurvival activity. WEHI 539 will be an invaluable tool for distinguishing the roles of BCL X(L) from those
US$ 150.50
US$ 115.00
US$ 49.00
US$ 370.00
US$ 179.99
US$ 185.00
US$ 235.00
US$ 248.50
US$ 80.99
US$ 155.00
US$ 106.50